# 510(k) Summary of Safety and Effectiveness for the

# ADVIA® Centaur Syphilis Assay

This summary of $5 1 0 ( \mathsf { k } )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

A. 510(k) Number: k112343   
B. Date of Preparation: November 1, 2011   
C. Proprietary and Established Names: ADVIA $^ \mathrm { \textregistered }$ Centaur Syphilis Assay ADVIA $\textsuperscript { \textregistered }$ Centaur Syphilis Quality Control Materials

D. Applicant: Siemens Healthcare Diagnostics Inc., 511 Benedict Ave, Tarrytown, NY 10591 Kira Gordon, Sr. Regulatory Affairs Specialist Office: (914) 524-2996 Fax: (914) 524-2500

# E. Regulatory Information:

ADVIA $\textsuperscript { \textregistered }$ Centaur Syphilis Assay (reagents and calibrators)   
1. Regulation section: 21 CFR $\ S 8 6 6 . 3 8 3 0$ Treponema pallidum treponemal test reagents   
2. Classification: Class II.   
3. Product Code: LIP, enzyme linked immunoabsorption assay, treponema pallidum   
4. Panel: Microbiology

ADVIA $\textsuperscript { \textregistered }$ Centaur Syphilis Quality Control Materials 1. Regulation section: 21 CFR $\$ 862.1660$ Quality control material (assayed and unassayed). 2. Classification: Class I 3. Product Code: MJY; Kit, serological, negative control MJX; Kit, serological, positive control 4. Panel: Microbiology

# F. Predicate Device:

ADVIA $\textsuperscript { \textregistered }$ Centaur Syphilis Assay (reagents and calibrators) and ADVIA $\otimes$ Centaur Syphilis Quality Control Materials are substantially equivalent to the IMMULITE 2000 Syphilis Screen Test System cleared under k091361

# G. Device Description:

The ADVIA Centaur syphilis assay is a fully automated, antigen sandwich assay, using direct chemiluminometric technology. The ancillary pack reagent containing acridinium-ester-labeled T. pallidum recombinant antigens is added to the sample.

These T. pallidum antigens complex with the antibodies in the sample. The solid phase containing biotinylated T. pallidum recombinant antigens preformed to streptavidin-coated magnetic latex particles, is then added to the sample. These particles capture the T. pallidum antigen-antibody complexes. Antibody-antigen complexes will form if Syphilis antibodies are present in the sample. A direct relationship exists between the level of antibodies to T. pallidum present in the patient sample and the amount of relative light units (RLUs) detected by the system. A result of reactive, nonreactive, or equivocal is determined according to the Index Value established with the calibrators.

The Syphilis kit contains the following:

- I ReadyPack $\textcircled{8}$ primary reagent pack containing ADVIA Centaur Syphilis Solid Phase Reagent $( 2 0 ~ \mathrm { m L } )$ :

- 1 Ancillary pack containing ADVIA Centaur Syphilis Ancillary Reagent (10mL)

- ADVIA Centaur Syphilis Master Curve card - 2 vials of Syphilis Low Calibrator $2 \ m L$ fill volume)

- 2 vials of Syphilis High Calibrator $2 \mathrm { m L }$ fill volume)

- ADVIA Centaur Syphilis Calibrator Assigned Value cards

In addition Syphilis quality control materials (2 vials of negative control and 2 vials of positive control with $7 m L$ fill volume each) are provided separately.

# H. Intended Use:

The ADVIA Centaur Syphilis (SYPH) assay is an in-vitro diagnostics immunoassay for the qualitative determination of antibodies to Treponema pallidum in human serum or plasma (EDTA, lithium or sodium heparinized, citrate) using the ADVIA Centaur $\textsuperscript { \textregistered }$ and ADVIA Centaur $\textsuperscript { \textregistered }$ XP systems as an aid in the diagnosis of syphilis. The ADVIA Centaur Syphilis assay is not intended for blood and tissue donor screening.

ADVIA® Centaur Syphilis Quality Control Materials are for in-vitro diagnostics use to monitor the performance of the Syphilis assay on the ADVIA Centaur $\textsuperscript { \textregistered }$ systems. The performance of the SYPH quality control material has not been established with any other Syphilis assay.

# I. Substantial Equivalence Information:

Both the predicate device and ADVIA Centaur Syphilis assay employ prepackaged reagents, calibrators and controls for use on automated test systems. A comparison of the important similarities and differences of these assays is provided in the following table:

<table><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">New Device:</td><td colspan="1" rowspan="1">Predicate Device:</td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">antibodies to Treponema pallidum</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">For in vitro diagnostic use in the</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">qualitative determination ofantibodies to Treponema pallidum</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Measurement</td><td colspan="1" rowspan="1">qualitative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Assay type</td><td colspan="1" rowspan="1">direct sandwich immunoassay basedon chemiluminescent technology</td><td colspan="1" rowspan="1">Enzyme labeled, one-stepchemiluminescent immunoassay</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">Serum , Heparinized Plasma, EDTAplasma, citrate plasma</td><td colspan="1" rowspan="1">Serum , Heparinized Plasma</td></tr><tr><td colspan="1" rowspan="1">Instrument to beused</td><td colspan="1" rowspan="1">ADVIA Centaur</td><td colspan="1" rowspan="1">IMMULITE 2000</td></tr><tr><td colspan="1" rowspan="1">Capture/DetectionAntigen/Antibody</td><td colspan="1" rowspan="1">Reagent: recombinant antigensTpN17 and TpN15 as biotinconjugatesAncillary pack: recombinantantigens TpN17 and TpN15 asacridinium ester conjugates</td><td colspan="1" rowspan="1">Beads coated with purifiedrecombinant antigen TpN17 arelinked to enzyme conjugatedpurified recombinant TpN17antigen in the reagent.</td></tr><tr><td colspan="1" rowspan="1">Cut-Offs</td><td colspan="1" rowspan="1">&lt; 0.9 Non-reactive≥ 0.9 to &lt; 1.1 Equivocal≥ 1.1 Reactive</td><td colspan="1" rowspan="1">&lt; 0.9 Non-reactive≥ 0.9 to &lt; 1.1 Indeterminate≥ 1.1 Reactive</td></tr><tr><td colspan="1" rowspan="1">Sample Volume</td><td colspan="1" rowspan="1">100 μL</td><td colspan="1" rowspan="1">100 μL</td></tr><tr><td colspan="1" rowspan="1">Interference</td><td colspan="1" rowspan="1">Not affected by hemolysis, icterus orlipemia at test levels</td><td colspan="1" rowspan="1">Not affected by hemolysis, icterusor lipemia at test levels</td></tr><tr><td colspan="1" rowspan="1">Hook Effect</td><td colspan="1" rowspan="1">None observed</td><td colspan="1" rowspan="1">None observed</td></tr><tr><td colspan="1" rowspan="1">Use of Calibrators</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Calibrators matrix</td><td colspan="1" rowspan="1">Human plasma</td><td colspan="1" rowspan="1">Human serum</td></tr><tr><td colspan="1" rowspan="1">Number ofcalibrators</td><td colspan="1" rowspan="1">two</td><td colspan="1" rowspan="1">one</td></tr><tr><td colspan="1" rowspan="1">Calibrator fillvolume</td><td colspan="1" rowspan="1">Liquid, 2 mL</td><td colspan="1" rowspan="1">Lyophilized, 4 mL</td></tr><tr><td colspan="1" rowspan="1">Use of controls</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Number of controls</td><td colspan="1" rowspan="1">two</td><td colspan="1" rowspan="1">two</td></tr><tr><td colspan="1" rowspan="1">Control matrix</td><td colspan="1" rowspan="1">Human plasma</td><td colspan="1" rowspan="1">Human serum</td></tr><tr><td colspan="1" rowspan="1">Control fill volume</td><td colspan="1" rowspan="1">Liquid, 7 mL</td><td colspan="1" rowspan="1">Lyophilized, 6 mL</td></tr></table>

# J. Performance Characteristics

Substantial equivalence was demonstrated by testing several performance characteristics including imprecision, reproducibility, interfering and cross-reactive substances.

# a.Precision

Precision estimates were computed according to CLSI document EP05-A2, Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline. Within run and total imprecision were evaluated by testing 5 serum based samples (serum sample pools), 3 plasma based samples (2 controls. low and high. and one additional plasma pool) and 2 calibrators (low and high). The elevated levels were spiked with syphilis antigen to achieve appropriate concentrations. The samples were assayed in duplicate over the course of 20 days, two runs per day, for a total of 40 runs and 80 replicates.

<table><tr><td rowspan=2 colspan=1>Pool</td><td rowspan=2 colspan=1>#Repl.</td><td rowspan=2 colspan=1>Mean(Index)</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>BetweenRun</td><td rowspan=1 colspan=2>BetweenDay</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td></tr><tr><td rowspan=1 colspan=1>Calibrator High (plasma)(high positive)</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>8.16</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>1.67</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.78</td><td rowspan=1 colspan=1>0.26</td><td rowspan=1 colspan=1>3.20</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>3.69</td></tr><tr><td rowspan=1 colspan=1>Calibrator Low (plasma)(high negative)</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.68</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>1.81</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.83</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>2.65</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>3.32</td></tr><tr><td rowspan=1 colspan=1>Control Negative (plasma)(low negative)</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Control Positive (plasma)(moderate pos.)</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>3.84</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>1.50</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>3.22</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>3.69</td></tr><tr><td rowspan=1 colspan=1>Plasma sample (moderate positive)</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.99</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>1.44</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>1.05</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>2.93</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>3.43</td></tr><tr><td rowspan=1 colspan=1>Serum sample 1 (low negative)</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Serum sample 2 (high negative)</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.80</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>1.16</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.86</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>2.86</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>3.20</td></tr><tr><td rowspan=1 colspan=1>Serum sample 3 (low positive)</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.28</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>1.31</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.93</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>2.79</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>3.22</td></tr><tr><td rowspan=1 colspan=1>Serum sample 4 (high positive)</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>6.96</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>1.45</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>3.63</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>4.02</td></tr><tr><td rowspan=1 colspan=1>Serum sample 5 (high positive)</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>21.45</td><td rowspan=1 colspan=1>0.41</td><td rowspan=1 colspan=1>1.93</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>1.29</td><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>3.50</td><td rowspan=1 colspan=1>0.90</td><td rowspan=1 colspan=1>4.20</td></tr></table>

# b.Reproducibility

The reproducibility study was conducted using two different reagent lots at three external sites. The protocol was run over 10 days, 2 runs per day, and 4 replicates per run for the sample pools, and 8 replicates per run for the negative and positive control materials. Reproducibility data pooled across 3 Sites, data is presented separately for a representative reagent lot.

<table><tr><td rowspan=2 colspan=1>Pool</td><td rowspan=2 colspan=1>#Repl.</td><td rowspan=2 colspan=1>Mean</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Between Run</td><td rowspan=1 colspan=2>BetweenDay</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td></tr><tr><td rowspan=1 colspan=1>Negative Control (plasma)(low negative)</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 1 (low negative)</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>0.006</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 2 (high negative)</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 3 (low positive)</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>1.20</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 4 (high positive)</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>6.67</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 5 (high positive)</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>20.42</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.53</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>Positive Control (plasma)(moderate positive)</td><td rowspan=1 colspan=1>480</td><td rowspan=1 colspan=1>3.56</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>2.5</td></tr></table>

# c.Interference

Interference by endogenous substances in the ADVIA Centaur Syphilis assay was evaluated at three syphilis levels (negative, low positive and high positive) using a significance criterion of $> 1 0 \%$ variance from the control. Each serum pool was spiked with an interferent to the levels indicated in the table below.

<table><tr><td colspan="1" rowspan="1">Interferent</td><td colspan="1" rowspan="1">Tested concentration (up to)</td></tr><tr><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">500 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Conjugated Bilirubin</td><td colspan="1" rowspan="1">40 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Unconjugated Bilirubin</td><td colspan="1" rowspan="1">40 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Intralipid</td><td colspan="1" rowspan="1">1000 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Cholesterol, Total</td><td colspan="1" rowspan="1">400 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Gamma Globulin</td><td colspan="1" rowspan="1">60 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Protein, Total (HSA)</td><td colspan="1" rowspan="1">11 g/dL</td></tr><tr><td colspan="1" rowspan="1">Biotin</td><td colspan="1" rowspan="1">500 ng/mL</td></tr></table>

There was no indication of interference up to the levels claimed. For the Syphilis positive samples all results demonstrated $\leq 1 0 \%$ change in index value with the exception of gamma globulin at concentrations above $3 0 \mathrm { m g / d L }$ :

# d.Cross-reactivity

al $( 1 ^ { s t } , 2 ^ { \mathsf { n d } }$ and $3 ^ { \mathsf { r d } }$ trimester), samples from hospitalized patients, pediatric samples and transplant samples were tested using the ADVIA Centaur Syphilis assay and the predicate device (predicate device). Each sample was tested in singlicate using one lot of reagent on one system. Predicate device and Centaur Syphilis results were determined reactive, non-reactive or indeterminate/equivocal according to the respective result interpretation.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Number of Reactive results</td></tr><tr><td rowspan=1 colspan=1>Clinical Category</td><td rowspan=1 colspan=1>Total NumberTested</td><td rowspan=1 colspan=1>CentaurSyphilis</td><td rowspan=1 colspan=1>Predicatedevice</td></tr><tr><td rowspan=1 colspan=1>Cord Blood</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>1st Trimester</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>2nd Trimester</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>3rd Trimester</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Pediatric</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Hospitalized</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>2*</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=4>Transplant Patients</td></tr><tr><td rowspan=1 colspan=1>Heart</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Kidney</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Liver</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Lung</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>.0</td></tr></table>

\* - positive on predicate device as well

265 specimens from 20 groups of potential cross-reactant disease states were assayed using the ADVIA Centaur Syphilis assay and the predicate device. These samples had a known activity to the potential cross reactant in each group of specimens which was determined by FDA-cleared methods and provided by the respective vendor. Each sample was tested in singlicate using one lot of reagent. The predicate device and Centaur Syphilis results were determined reactive, non-reactive or indeterminate/equivocal according to the respective result interpretation method.

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">Number of Reactiveresults</td></tr><tr><td colspan="1" rowspan="1">Clinical Category</td><td colspan="1" rowspan="1">Total NumberTested</td><td colspan="1" rowspan="1">CentaurSyphilis</td><td colspan="1" rowspan="1">Predicatedevice</td></tr><tr><td colspan="1" rowspan="1">Lyme Disease</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">1*</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Anti-Nuclear Antibody (ANA)</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Rheumatoid Factor</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">HAMA</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">2*</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1">Hepatitis A Infection (HAV) total</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">10*</td><td colspan="1" rowspan="1">10</td></tr><tr><td colspan="1" rowspan="1">Hepatitis A Infection (HAV) IgM</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Hepatitis B Infection (HBV)</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Hepatitis C Infection (HCV)</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Human Immunodeficiency Virus (HIV)</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirus (CMV) IgG</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirus (CMV) IgM</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Epstein-Barr Virus (EBV) IgG</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Herpes Simplex Virus (HSV) IgG</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">5*</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="1">Rubella IgG</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Rubella IgM</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Toxoplasma IgG</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">1*</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Toxoplasma IgM</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Varicella Zoster Virus (VZV) IgG</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">2*</td><td colspan="1" rowspan="1">2</td></tr><tr><td colspan="1" rowspan="1">Lupus (SLE)</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Drug users</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">3*</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">Myeloma patients</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Flu Vaccine recipients</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Hyper-IgG</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Hyper-IgM</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr></table>

\* - positive on predicate device as well. \* - all samples that demonstrated a positive result (with the exception of two HA V-positive samples) were also confirmed positive by other tests (TPPA or RRP), indicating reactivity to Syphilis (T. Pallidum antibodies) rather than cross reactivity.

# K. Clinical evaluation

As part of the clinical study, samples from various patient populations were tested at three clinical trial sites with both the ADVIA Centaur Syphilis assay and the predicate device. Results are summarized in the following tables.

# Method Comparison, All Sites pooled

<table><tr><td></td><td colspan="3">Predicate Device</td></tr><tr><td>ADVIA Centaur System</td><td>Reactive</td><td>Indeterminate</td><td>Nonreactive Total</td></tr><tr><td>Reactive</td><td>700</td><td>1</td><td>6 707</td></tr><tr><td>Equivocal</td><td>1</td><td>3</td><td>4</td></tr><tr><td>Nonreactive Total 715</td><td>14</td><td>1 1382</td><td>1397</td></tr></table>

The negative percent agreement was $9 9 . 4 \%$ (1382/1391) with a $9 5 \%$ confidence interval (Cl) of 98.8 to $9 9 . 7 \%$ . The positive percent agreement was $9 7 . 9 \%$ (700/715) with a $9 5 \%$ confidence interval (CI) of 96.6 to $9 8 . 8 \%$ .

Method Comparison, Expected Positive Population   

<table><tr><td colspan="6">Expected Positive Positive Percent</td></tr><tr><td>Subjects TPPA-</td><td>Reactive</td><td>Equivocal</td><td>Nonreactive</td><td>Total</td><td>Agreement</td></tr><tr><td>Reactive</td><td>271 (98.2%)</td><td>1 (0.4%)</td><td>4 (1.4%)</td><td>276</td><td>99.6% (271/272)</td></tr><tr><td>Medically Diagnosed</td><td>264 (92.6%)</td><td>0 (0.0%)</td><td>21 (7.4%)</td><td>285</td><td>99.2% (264/266)</td></tr><tr><td>Total</td><td>535 (95.4%)</td><td>1 (0.2%)</td><td>25 (4.5%)</td><td>561</td><td>99.4% (535/538)</td></tr></table>

The $\%$ positive agreement was $9 9 . 4 \%$ (535/538) with a $9 5 \%$ confidence interval with a $9 5 \%$ confidence interval (Cl) of 98.4 to $9 9 . 9 \%$ , and the $\%$ negative agreement was $100 \%$ (23/23) with a $9 5 \%$ confidence interval (Cl) of 85.2 to $1 0 0 . 0 \%$ .

Method Comparison, Samples Sent for Syphilis Testing   

<table><tr><td colspan="4">Predicate device</td></tr><tr><td>ADVIA Centaur System</td><td>Reactive</td><td>Indeterminate</td><td>Nonreactive Total</td></tr><tr><td>Reactive</td><td>160</td><td></td><td>6 167</td></tr><tr><td>Equivocal</td><td>0</td><td>0</td><td>3 3</td></tr><tr><td>Nonreactive Total</td><td>3 163</td><td>0</td><td>568 571 577 741</td></tr></table>

The $\%$ positive agreement was $9 8 . 2 \%$ (160/163) with a $9 5 \%$ confidence interval (Cl) of 94.7 to $9 9 . 6 \%$ , and the $\%$ negative agreement was $9 8 . 4 \%$ (568/577) with a $9 5 \%$ EPY confidence interval (Cl) of 97.1 to $9 9 . 3 \%$ .

# Conclusion:

Comparative testing of the ADVIA Centaur Syphilis assay is substantially equivalent in principle and performance to the predicate device.

Kira Gordon   
Regulatory Affairs & Compliance   
November 1, 2011   
Siemens Healthcare Diagnostics, Inc   
Kira Gordon   
Senior Regulatory Affairs Specialist   
511 Benedict Ave   
Tarrytown, NY 10591

# JAN 2 0 2012

Re: K112343 Trade/Device Name: ADVIA Centaur Syphilis Assay Regulation Number: 21 CFR § 866.3830 Regulation Name: Treponema pallidum treponemal test reagents Regulatory Class: Class ⅡI Product Code: LIP Dated: January 17, 2012 Received: January 18, 2012

Dear Dr. Gordon:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket

Page 2 - Dr. Kira Gordon

notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.   
Sincerely yours,   
fay atys   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Indications For Use

510(k) Number: k112343

Device Name:

# ADVIA $\textsuperscript { \textregistered }$ Centaur Syphilis assay ADVIA® Centaur Syphilis Quality Control Materials

Indications For Use:

The ADVIA Centaur Syphilis assay:

The ADVIA Centaur Syphilis (SYPH) assay is an in-vitro diagnostic immunoassay for the qualitative determination of antibodies to Treponema pallidum in human serum or plasma (EDTA, lithium or sodium heparinized, citrate) using the ADVIA Centaur® and ADVIA Centaur® XP systems as an aid in the diagnosis of syphilis.

The ADVIA Centaur Syphilis assay is not intended for blood and tissue donor screening.

ADVIA Centaur Syphilis Quality Control Materials:

ADVIA® Centaur Syphilis Quality Control Materials are for in-vitro diagnostic use to monitor the performance of the Syphilis assay on the ADVIA Centaur® systems. The performance of the SYPH quality control material has not been established with any other Syphilis assay.